Peck G - Search Results

1

Isotretinoin-basal cell carcinoma prevention trial. Design, recruitment results, and baseline characteristics of the trial participants. The ISO-BCC Study Group.

Tangrea J, Edwards B, Hartman A, Taylor P, Peck G, Salasche S, Menon P, Winton G, Mellette R, Guill M, et al. Tangrea J, et al. Among authors: peck g. Control Clin Trials. 1990 Dec;11(6):433-50. doi: 10.1016/0197-2456(90)90020-3. Control Clin Trials. 1990. PMID: 1963135 Clinical Trial.

2

Clinical and laboratory adverse effects associated with long-term, low-dose isotretinoin: incidence and risk factors. The Isotretinoin-Basal Cell Carcinomas Study Group.

Tangrea JA, Adrianza E, Helsel WE, Taylor PR, Hartman AM, Peck GL, Edwards BK. Tangrea JA, et al. Among authors: peck gl. Cancer Epidemiol Biomarkers Prev. 1993 Jul-Aug;2(4):375-80. Cancer Epidemiol Biomarkers Prev. 1993. PMID: 8348061 Clinical Trial.

3

Skeletal hyperostosis in patients receiving chronic, very-low-dose isotretinoin.

Tangrea JA, Kilcoyne RF, Taylor PR, Helsel WE, Adrianza ME, Hartman AM, Edwards BK, Peck GL. Tangrea JA, et al. Among authors: peck gl. Arch Dermatol. 1992 Jul;128(7):921-5. Arch Dermatol. 1992. PMID: 1626958 Clinical Trial.

4

Long-term therapy with low-dose isotretinoin for prevention of basal cell carcinoma: a multicenter clinical trial. Isotretinoin-Basal Cell Carcinoma Study Group.

Tangrea JA, Edwards BK, Taylor PR, Hartman AM, Peck GL, Salasche SJ, Menon PA, Benson PM, Mellette JR, Guill MA, et al. Tangrea JA, et al. Among authors: peck gl. J Natl Cancer Inst. 1992 Mar 4;84(5):328-32. doi: 10.1093/jnci/84.5.328. J Natl Cancer Inst. 1992. PMID: 1738183 Clinical Trial.

5

Isotretinoin and the axial skeleton.

Tangrea JA, Taylor PR, Hartman AM, Edwards BK, Kilcoyne RF, Helsel WE, Adrianza ME, Peck GL. Tangrea JA, et al. Among authors: peck gl. Lancet. 1992 Aug 22;340(8817):495-6. doi: 10.1016/0140-6736(92)91825-s. Lancet. 1992. PMID: 1354829 No abstract available.

6

Treatment and prevention of basal cell carcinoma with oral isotretinoin.

Peck GL, DiGiovanna JJ, Sarnoff DS, Gross EG, Butkus D, Olsen TG, Yoder FW. Peck GL, et al. J Am Acad Dermatol. 1988 Jul;19(1 Pt 2):176-85. doi: 10.1016/s0190-9622(88)70162-0. J Am Acad Dermatol. 1988. PMID: 3165982

7

Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin.

Kraemer KH, DiGiovanna JJ, Moshell AN, Tarone RE, Peck GL. Kraemer KH, et al. Among authors: peck gl. N Engl J Med. 1988 Jun 23;318(25):1633-7. doi: 10.1056/NEJM198806233182501. N Engl J Med. 1988. PMID: 3287161 Clinical Trial.

8

Chemoprevention of skin cancer in xeroderma pigmentosum.

Kraemer KH, DiGiovanna JJ, Peck GL. Kraemer KH, et al. Among authors: peck gl. J Dermatol. 1992 Nov;19(11):715-8. doi: 10.1111/j.1346-8138.1992.tb03766.x. J Dermatol. 1992. PMID: 1293159

9

Long-term retinoid therapy is needed for maintenance of cancer chemopreventive effect.

Peck GL. Peck GL. Dermatologica. 1987;175 Suppl 1:138-44. doi: 10.1159/000248870. Dermatologica. 1987. PMID: 3480250

10

Acute depression from isotretinoin.

Scheinman PL, Peck GL, Rubinow DR, DiGiovanna JJ, Abangan DL, Ravin PD. Scheinman PL, et al. Among authors: peck gl. J Am Acad Dermatol. 1990 Jun;22(6 Pt 1):1112-4. doi: 10.1016/s0190-9622(08)81018-3. J Am Acad Dermatol. 1990. PMID: 2142496 Clinical Trial. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

340 results

Search Page

Filters